High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia

American Journal of Obstetrics and Gynecology

Volumn 180, Issue 5, 1999, Pages 1146-1150

  Van Pampus, Maria G ^a   Dekker, Gustaf A ^b   Wolf, Hans ^b   Huijgens, Peter C ^b   Koopman, Maria M W ^b   Von Blomberg, B Mary E ^b   Büller, Harry R ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Activated protein C resistance; Anticardiolipin antibodies; Factor V mutation; Hyperhomocysteinemia; Preeclampsia

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE;

ARTICLE; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MUTATION; PREECLAMPSIA; PREVALENCE; PRIORITY JOURNAL;

EID: 0033000764     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(99)70608-3     Document Type: Article

References (22)

1. 1. Saftlas AF, Olson DR, Franks AL, Atrash H, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 1990;163:460-5.
2. 2. Weinstein I. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982;142:159-67.
3. 3. Roberts JM, Redman CW, Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993;341:1447-54.
4. 4. Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BME, Jakobs C, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-8.
5. 5. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348:913-6.
6. 6. Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A, et al. The risk of abortion and stillbirth in antithrombin-, protein C-and protein S-deficient women, Thromb Haemost 1996;75:387-8.
7. 7. Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 1997;176:457-60.
8. 8. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996;175:902-5.
9. 9. Wouters MGAJ, Boers GHJ, Blom HJ, Trijbels FJ, Thomas CM, Borm GF, et al. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993;60:820-5.
10. 10. Steegers-Theunissen RPM, Boers GHJ, Blom HJ, Trijbels FJM, Eskes TKAB. Hyperhomocysteinemia and recurrent abortion or abruptio placentae. Lancet 1992;339:1122-3.
11. 11. Pattison NS, Birdsall MA, Chamley LW. Recurrent fetal loss and the antiphospholipid syndrome. Rec Adv Obstet Gynaecol 1994;18:23-50.
12. 12. Kloosterman GJ. On intrauterine growth. Int J Gynaecol Obstet 1970;8:895-12.
13. 13. Dahlbäck H, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-8.
14. 14. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis dur to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
15. 15. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, et al. Association of idiopathic venous thromboembolism with single point mutation at ARG of factor V. Lancet 1994;343:1535-6.
16. 16. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocysteinuria due to cystathionine-synthase deficiency. Am J Hum Genet 1985;37:1-31.
17. 17. Ubbink JB, Vermaak WJK, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human semm. J Chromatogr 1991;565:441-6.
18. 18. Harris EN, Phil M. Special report: The Second International Anti-Cardiolipin Standardization Workshop/The Kingston Anti-Phospholipid Antibody Study (KAPS) Group. Am J Clin Pathol 1990;94:476-81.
19. 19. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
20. 20. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996;125:265-9.
21. 21. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-9.
22. 22. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253-7.